Diverse Biotech Inc, a United States-based biopharmaceutical company, has named Stella Vnook as its new chief executive officer, it was reported yesterday.
Vnook has more than 25 years' experience. She has most recently held senior leadership roles at Assertio Pharma, Jazz Pharmaceuticals, Catalent and Merck. She started her career in Research and Development in the Emergency Department at Temple University Hospital and later continued that work with oncology specialty interest at Temple/Fox Chase Cancer Centre as a pharmacist. Throughout her career she has developed extensive knowledge in many different therapy categories with a particular emphasis on Oncology, Pain Management and Cardiovascular Diseases.
William Fisher, Diverse Biotech's board chairman, said, 'Diverse Biotech is very excited to bring Stella on board as an experienced, knowledgeable, and innovative Senior Leader. Stella will work hand in hand with the current Diverse Biotech Board to continue to build a world class, innovative, experienced Executive Team.'
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes